Connect
MJA
MJA

Antivenom dosing in 35 patients with severe brown snake (Pseudonaja) envenoming in Western Australia over 10 years

Justin M Yeung, Frank F S Daly, Mark Little, Lindsay M Murray and George A Jelinek
Med J Aust 2004; 181 (11): 703-705.

Summary

Objective: To investigate the doses of antivenom administered to adult patients with severe brown snake envenoming.

Design and setting: Review of charts from Western Australian adult teaching hospitals, December 1991 to December 2001.

Patients: 35 patients with severe brown snake envenoming, defined prospectively as afibrinogenaemia (< 0.3 g/L) after a bite by a brown snake (genus Pseudonaja).

Main outcome measure: The dose of antivenom required to neutralise venom, defined prospectively as the dose of antivenom given before the return of detectable fibrinogen levels.

Results: Of 88 patients with brown snake envenoming admitted over the 10 years, at least 35 had severe envenoming. Afibrinogenaemia persisted for 10 hours (range, 1.4–68 hours) after the first dose of antivenom; in four patients afibrinogenaemia lasted more than 24 hours. The dose of antivenom given before venom neutralisation ranged from one to 23 ampoules. In two-thirds of cases, venom was neutralised with five ampoules, and 89% had venom neutralised with 10 ampoules. Two patients died, and another had serious bleeding complications. Another patient died during the study period from intracerebral haemorrhage, but did not have fibrinogen levels measured.

Conclusions: Patients received initial doses of antivenom too small to neutralise circulating venom, and remained afibrinogenaemic for prolonged periods, with serious consequences. The authors now use 10 ampoules as an initial dose in severe brown snake envenoming.

Please login with your free MJA account to view this article in full

  • Justin M Yeung1
  • Frank F S Daly2
  • Mark Little3
  • Lindsay M Murray4
  • George A Jelinek5

  • 1 Department of Emergency Medicine, Royal Perth Hospital, Perth, WA.
  • 2 Department of Emergency Medicine, Sir Charles Gairdner Hospital, Nedlands, WA.

Correspondence: 

Competing interests:

None identified.

  • 1. White J. Antivenom handbook. Melbourne: CSL Ltd, 2001.
  • 2. Australian Venom Research Unit. Notes on the medical management of Australian venomous snake bites. Available at: www.avru.unimelb. edu.au/avruweb/doctors.htm (accessed Dec 2003).
  • 3. Product information. Brown snake antivenom. Melbourne: CSL Ltd, 2000.
  • 4. Theakston RD. An objective approach to antivenom therapy and assessment of first-aid measures in snake bite. Ann Trop Med Parasitol 1997; 91: 857-865.
  • 5. Sprivulis PC, Jelinek GA, Marshall L. Efficacy and potency of antivenoms in neutralising the procoagulant effects of Australian snake venoms in dog and human plasma. Anaesth Intensive Care 1996; 24: 379-381.
  • 6. Tibballs J, Sutherland SK. The efficacy of antivenom in prevention of cardiovascular depression and coagulopathy induced by brown snake (Pseudonaja) species venom. Anaesth Intensive Care 1991; 19: 530-534.
  • 7. Barrett RL, Little M. Five years of snake envenoming in far north Queensland. Emerg Med 2003; 15: 500-510.
  • 8. Jelinek GA, Hamilton T, Hirsch RL. Admissions for suspected snake bite to the Perth adult teaching hospitals, 1979 to 1988. Med J Aust 1991; 155: 761-764.
  • 9. White J. Management of brown snake envenoming. Crit Care Resus 2002; 4: 81-86.
  • 10. Gilbert EH, Lowenstein SR, Koziol-McLain J, et al. Chart reviews in emergency medicine research: where are the methods? Ann Emerg Med 1996; 27: 305-308.
  • 11. Sprivulis PC, Jelinek GA. Fatal intracranial haematomas in two patients with brown snake envenomation. Med J Aust 1995; 162: 215-216.
  • 12. Jelinek GA, Smith A, Lynch D, et al. The effect of adjunctive fresh frozen plasma administration on coagulation parameters and survival in a canine model of antivenom-treated Brown snake envenoming. Anaesth Intensive Care 2004. In press.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.